Betta Pharmaceuticals ^Investor

Betta Pharmaceuticals is a state-level hi-tech pharmaceutical enterprise that focuses on the research and development of innovative medicines. Established in 2003 by a team of returned PhD holders, the company is dedicated to addressing diseases that severely impact human health, such as malignant tumors, diabetes, and cardio-cerebrovascular disease. Betta Pharmaceuticals has achieved significant milestones, including the successful listing on the GEM of Shenzhen Stock Exchange in 2016. Their flagship product, Icotinib Hydrochloride (Conmana), has received international recognition and numerous awards for its contribution to the field of anti-cancer drugs. With over 100 authorized patents and a commitment to innovation, Betta Pharmaceuticals aims to become a transnational pharmaceutical enterprise headquartered in China, providing affordable and high-quality medicines to the public.